Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study

[1]  J. Boivin,et al.  Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Cole,et al.  Statistics Notes: Percentage differences, symmetry, and natural logarithms , 2017, British Medical Journal.

[3]  K. Czene,et al.  Cohort Profile Cohort Profile : The Karolinska Mammography Project for Risk Prediction of Breast Cancer ( KARMA ) , 2017 .

[4]  Nico Karssemeijer,et al.  Volumetric breast density affects performance of digital screening mammography , 2016, Breast Cancer Research and Treatment.

[5]  A. Tjønneland,et al.  Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort , 2016, Cancer Causes & Control.

[6]  Dennis J. Hazelett,et al.  The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[7]  S. Suissa,et al.  Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies , 2016, Diabetes Care.

[8]  K. Hemminki,et al.  Subsequent Type 2 Diabetes in Patients with Autoimmune Disease , 2015, Scientific Reports.

[9]  M. Schmidt,et al.  Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence , 2015, Breast Cancer Research.

[10]  J. Perry,et al.  Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis , 2015, Journal of the National Cancer Institute.

[11]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[12]  Jingmei Li,et al.  Digital mammographic density and breast cancer risk: a case–control study of six alternative density assessment methods , 2014, Breast Cancer Research.

[13]  Kamila Czene,et al.  Automated Measurement of Volumetric Mammographic Density: A Tool for Widespread Breast Cancer Risk Assessment , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[14]  S. Yusuf,et al.  The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia , 2014, Diabetes Care.

[15]  Haibo Zhou,et al.  Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin , 2013, Diabetes Care.

[16]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[17]  V. Formica,et al.  Insulinemia and the risk of breast cancer and its relapse , 2012, Diabetes, obesity & metabolism.

[18]  D. Rose,et al.  The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. , 2012, Endocrine-related cancer.

[19]  Tanya M. Teslovich,et al.  Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways , 2012, Nature Genetics.

[20]  N. Boyd,et al.  Mammographic density and breast cancer risk: current understanding and future prospects , 2011, Breast Cancer Research.

[21]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[22]  S. Suissa,et al.  Long-term effects of insulin glargine on the risk of breast cancer , 2011, Diabetologia.

[23]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[24]  H. Werner,et al.  Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor , 2010, Diabetologia.

[25]  Nico Karssemeijer,et al.  Robust breast composition measurement - Volpara™ , 2010 .

[26]  D. Harlan,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[27]  Nico Karssemeijer,et al.  Robust Breast Composition Measurement - VolparaTM , 2010, Digital Mammography / IWDM.

[28]  Mimi Y. Kim,et al.  Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer , 2009, International journal of cancer.

[29]  J. McGill,et al.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study , 2009, Diabetologia.

[30]  R. Jiménez-García,et al.  Prevalence and Predictors of Breast and Cervical Cancer Screening Among Spanish Women With Diabetes , 2009, Diabetes Care.

[31]  Thomas E Rohan,et al.  Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. , 2009, Journal of the National Cancer Institute.

[32]  P. Pisani.  Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies , 2008, Archives of physiology and biochemistry.

[33]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[34]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[35]  V. McCormack,et al.  Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[36]  J. Hux,et al.  Reduced screening mammography among women with diabetes. , 2005, Archives of internal medicine.

[37]  A. Paterson,et al.  Mammographic breast density as an intermediate phenotype for breast cancer. , 2005, The Lancet. Oncology.

[38]  D. Lawlor,et al.  Hyperinsulinaemia and Increased Risk of Breast Cancer: Findings From the British Women's Heart and Health Study , 2004, Cancer Causes & Control.

[39]  H. Adami,et al.  Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. , 2003, Journal of the National Cancer Institute.

[40]  A. Folsom,et al.  Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. , 2002, American journal of epidemiology.

[41]  M. Goalstone,et al.  Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. , 2001, The Journal of biological chemistry.

[42]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[43]  C. Christoffersen,et al.  Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor , 1997, Diabetologia.

[44]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.